Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Paxlovid (nirmatrelvir / ritonavir)
- Zetia (ezetimibe)
Interactions between your drugs
ritonavir ezetimibe
Applies to: Paxlovid (nirmatrelvir / ritonavir), Zetia (ezetimibe)
Ritonavir may increase the blood levels and effects of ezetimibe. This may increase your chances of experiencing serious, but relatively rare side effects such as liver damage or a condition that involves the breakdown of skeletal muscle tissue known as rhabdomyolysis. You may need more frequent monitoring by your healthcare provider to safely use both medications. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness while taking these medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
ritonavir food
Applies to: Paxlovid (nirmatrelvir / ritonavir)
Ritonavir should be taken with food to lessen gastrointestinal side effects. It is important that you take this medication exactly as prescribed by your doctor. Do not change your treatment or stop treatment without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Actemra
Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Tyenne
Tyenne is approved to treat adults with moderately to severely active rheumatoid arthritis, Giant ...
Olumiant
Olumiant is used to treat rheumatoid arthritis, alopecia areata (hair loss), and COVID-19. Includes ...
Kineret
Kineret is used to treat the symptoms of moderate to severe rheumatoid arthritis ...
Veklury
Veklury is used to treat COVID-19 in adults and children from birth who weigh at least 3.3 pounds ...
Anakinra
Anakinra is used for COVID-19, cryopyrin-associated periodic syndromes, interleukin-1 receptor ...
Baricitinib
Baricitinib (brand name Olumiant) is used to treat rheumatoid arthritis, alopecia areata (hair ...
Molnupiravir
Molnupiravir is an experimental medicine being studied for the treatment of mild-to-moderate ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.